J F Trotter1, M Levi, T Steinberg, J Lancaster. 1. Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, 1635 N. Ursula, B-154, Aurora, CO 80045, USA. james.trotter@uchsc.edu
Abstract
UNLABELLED: Pneumocystis jiroveci (formerly known as Pneumocystis carinii) is a fungal pathogen that causes pneumonia (PCP) in liver transplant recipients. Consequently, prophylaxis with trimethoprim-sulfamethoxazole (TMP/SMZ) is typically administered for at least 1 year at most liver transplant programs. At our center we have utilized a short-term (3-month) prophylactic regimen with TMP/SMZ for the past decade and report our experience and speculate on the potential widespread application of this approach. METHODS: For patients transplanted at our center between January 1997 and January 2007, we recorded all documented PCP infections by review of our liver transplant database and hospital-based electronic medical records system, both of which record all infections and culture results. RESULTS: We recorded no cases of PCP in any of the liver transplant recipients at our center during the study period. CONCLUSIONS: We report the absence of PCP in a large cohort of liver transplant recipients receiving a short-term (3-month) prophylaxis with TMP/SMZ. These findings provide a rational basis to consider short-term (3-month) PCP prophylaxis or avoidance of prophylaxis altogether in selected low-risk patients.
UNLABELLED: Pneumocystis jiroveci (formerly known as Pneumocystis carinii) is a fungal pathogen that causes pneumonia (PCP) in liver transplant recipients. Consequently, prophylaxis with trimethoprim-sulfamethoxazole (TMP/SMZ) is typically administered for at least 1 year at most liver transplant programs. At our center we have utilized a short-term (3-month) prophylactic regimen with TMP/SMZ for the past decade and report our experience and speculate on the potential widespread application of this approach. METHODS: For patients transplanted at our center between January 1997 and January 2007, we recorded all documented PCP infections by review of our liver transplant database and hospital-based electronic medical records system, both of which record all infections and culture results. RESULTS: We recorded no cases of PCP in any of the liver transplant recipients at our center during the study period. CONCLUSIONS: We report the absence of PCP in a large cohort of liver transplant recipients receiving a short-term (3-month) prophylaxis with TMP/SMZ. These findings provide a rational basis to consider short-term (3-month) PCP prophylaxis or avoidance of prophylaxis altogether in selected low-risk patients.
Authors: Andreas A Rostved; Monica Sassi; Jørgen A L Kurtzhals; Søren Schwartz Sørensen; Allan Rasmussen; Christian Ross; Emile Gogineni; Charles Huber; Geetha Kutty; Joseph A Kovacs; Jannik Helweg-Larsen Journal: Transplantation Date: 2013-11-15 Impact factor: 4.939
Authors: José Ignacio Fortea; Antonio Cuadrado; Ángela Puente; Paloma Álvarez Fernández; Patricia Huelin; Carmen Álvarez Tato; Inés García Carrera; Marina Cobreros; María Luisa Cagigal Cobo; Jorge Calvo Montes; Carlos Ruiz de Alegría Puig; Juan Carlos Rodríguez SanJuán; Federico José Castillo Suescun; Roberto Fernández Santiago; Juan Andrés Echeverri Cifuentes; Fernando Casafont; Javier Crespo; Emilio Fábrega Journal: J Clin Med Date: 2020-11-06 Impact factor: 4.241